4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridazine, 95.0%, 5g

6-Nitro-2,3-dihydrophthalazine-1,4-dione, 95+%, 100g

6-hydrazinoimidazo[1,2-b]pyridazine, 95.0%, 10g

4-[4-[4,6-Bis[4-(4-carboxyphenyl)phenyl]-1,3,5-triazin-2-yl]phenyl]benzoic acid, 97%, 250mg

Recipiente de reacción con brida plana, cilíndrico, graduado, con camisa de templado y vacío y válvula de drenaje, DN 150, 100 ml, 120 mm, 1 pieza

6-Bromo-7-fluoroisoquinolin-1(2H)-one, 97%, 250mg

2-Ethoxycinnamic acid, 98+%, 99.0%, 1g

Alloc-Val-Cit-PAB-OH>96.0%(HPLC)(N)1g

3-Bromonaphthalene-2-carboxylic acid, 98%, 500mg

2-(ISOBUTYLAMINO)ACETIC ACID, 95.0%, 100mg

4-Chloro-3-trifluoromethylphenylboronic acid, 96.0%, 100g

2-O-alpha-D-Glucopyranosyl-L-ascorbic Acid>98.0%(HPLC)(T)1g

3-Carboxy-5-nitrophenylboronic acid, 97.0%, 100g